By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Sarajevo TimesSarajevo TimesSarajevo Times
  • HOME
  • POLITICS
    • BH & EU
  • BUSINESS
  • BH TOURISM
  • INTERVIEWS
    • BH & EU
    • BUSINESS
    • ARTS
  • SPORT
  • ARTS
    • CULTURE
    • ENTERTAINMENT
  • W&N
Search
  • ABOUT US
  • IMPRESSUM
  • NEWSLETTER
  • CONTACT
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Reading: EMA: AstraZeneca Vaccine is not associated with an Increase in the Overall Risk of blood Clots
Share
Font ResizerAa
Sarajevo TimesSarajevo Times
Font ResizerAa
  • HOME
  • POLITICS
  • BUSINESS
  • BH TOURISM
  • INTERVIEWS
  • SPORT
  • ARTS
  • W&N
Search
  • HOME
  • POLITICS
    • BH & EU
  • BUSINESS
  • BH TOURISM
  • INTERVIEWS
    • BH & EU
    • BUSINESS
    • ARTS
  • SPORT
  • ARTS
    • CULTURE
    • ENTERTAINMENT
  • W&N
Follow US
  • ABOUT US
  • IMPRESSUM
  • NEWSLETTER
  • CONTACT
© 2012 Sarajevo Times. All rights reserved.
Sarajevo Times > Blog > WORLD NEWS > EMA: AstraZeneca Vaccine is not associated with an Increase in the Overall Risk of blood Clots
WORLD NEWS

EMA: AstraZeneca Vaccine is not associated with an Increase in the Overall Risk of blood Clots

Published: March 18, 2021
Share
SHARE

EMA’s safety committee, PRAC, concluded its preliminary review of a signal of blood clots in people vaccinated with COVID-19 Vaccine AstraZeneca at its extraordinary meeting of 18 March 2021. The Committee confirmed that the benefits of the vaccine in combating the still widespread threat of COVID-19 (which itself results in clotting problems and may be fatal) continue to outweigh the risk of side effects.

The vaccine is not associated with an increase in the overall risk of blood clots (thromboembolic events) in those who receive it; there is no evidence of a problem related to specific batches of the vaccine or to particular manufacturing sites; however, the vaccine may be associated with very rare cases of blood clots associated with thrombocytopenia, i.e. low levels of blood platelets (elements in the blood that help it to clot) with or without bleeding, including rare cases of clots in the vessels draining blood from the brain (CVST).

These are rare cases – around 20 million people in the UK and EEA had received the vaccine as of March 16 and EMA had reviewed only 7 cases of blood clots in multiple blood vessels (disseminated intravascular coagulation, DIC) and 18 cases of CVST. A causal link with the vaccine is not proven, but is possible and deserves further analysis.

The PRAC involved experts in blood disorders in its review, and worked closely with other health authorities including the UK’s MHRA which has experience with administration of this vaccine to around 11 million people. Overall the number of thromboembolic events reported after vaccination, both in studies before licensing and in reports after rollout of vaccination campaigns (469 reports, 191 of them from the EEA), was lower than that expected in the general population. This allows the PRAC to confirm that there is no increase in overall risk of blood clots. However, in younger patients there remain some concerns, related in particular to these rare cases.

The Committee’s experts looked in extreme detail at records of DIC and CVST reported from Member States, 9 of which resulted in death. Most of these occurred in people under 55 and the majority were women. Because these events are rare, and COVID-19 itself often causes blood clotting disorders in patients, it is difficult to estimate a background rate for these events in people who have not had the vaccine. However, based on pre-COVID figures it was calculated that less than 1 reported case of DIC might have been expected by 16 March among people under 50 within 14 days of receiving the vaccine, whereas 5 cases had been reported. Similarly, on average 1.35 cases of CVST might have been expected among this age group whereas by the same cut-off date there had been 12. A similar imbalance was not visible in the older population given the vaccine.

The Committee was of the opinion that the vaccine’s proven efficacy in preventing hospitalisation and death from COVID-19 outweighs the extremely small likelihood of developing DIC or CVST. However, in the light of its findings, patients should be aware of the remote possibility of such syndromes, and if symptoms suggestive of clotting problems occur patients should seek immediate medical attention and inform healthcare professionals of their recent vaccination. Steps are already being taken to update the product information for the vaccine to include more information on these risks.

The PRAC will undertake additional review of these risks, including looking at the risks with other types of COVID-19 vaccines (although no signal has been identified from monitoring so far). Close safety monitoring of reports of blood clotting disorders will continue, and further studies are being instituted to provide more laboratory data as well as real-world evidence.  EMA will communicate further as appropriate.

All Employees of Parliament of BiH have to submit their Diplomas for Check!
Golden Visa Hungary: New €250K Investment Route Opens Doors to EU Residency
Export of Meat from Bosnia and Herzegovina increased 154 Percent
Blinken: What we no longer need is a return to the Past, to the Nineties
The Fair of “Golden Colors” opened on Bijambare
TAGGED:#astrazeneca#BiH#coronavirus#vaccine
Share This Article
Facebook Whatsapp Whatsapp Telegram Threads Bluesky Email Print
Share
What do you think?
Love0
Sad0
Happy0
Sleepy0
Angry0
Dead0
Wink0
Previous Article Center for digitalization, innovation and competitiveness of the Metal Industry opened in Zenica
Next Article Bosnia records a Decrease in the Average Monthly Earnings in January
Leave a Comment Leave a Comment

Leave a Reply Cancel reply

You must be logged in to post a comment.

Stay Connected

10.2KFollowersLike
10.1KFollowersFollow
414FollowersFollow

Latest News

RCC Survey: Western Balkan Citizens worried about cost of Living and Inflation
November 19, 2026
Inspiring Young People to Explore Their Future, EUFOR at Open Day in Brcko
November 19, 2026
Sarajevo hosts the International Logistics Conference with over 250 Participants
November 19, 2026
Pronouncement of the Verdict for Murder of Sarajevo Policemen scheduled
November 19, 2026
BiH Army Colonel Amer Rikovic awarded Prestigious Senior Lecturer Title at NATO School
November 19, 2026
The SDS withdrew its candidacy for the House of Peoples of the Parliamentary Assembly of BiH
November 19, 2026
Bosnia and Herzegovina Still Lacks National Cybersecurity Strategy, Experts Warn of Risks
November 19, 2026
Minimum Wage Negotiations: Take Care of the Worker, but also the Employers
November 19, 2026
Meeting of the Strategic Committee for Weapons, Ammunition, and Mine-Explosive Ordnance Held
November 18, 2026
Becirovic meets the Ambassador of the Republic of Italy Sarah Eti Castellani
November 18, 2026
Sarajevo TimesSarajevo Times
Follow US
© 2012 Sarajevo Times. All Rights Reserved.
  • ABOUT US
  • IMPRESSUM
  • NEWSLETTER
  • CONTACT
Go to mobile version
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?